Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension
Improved ten-year survival of systemic sclerosis-associated pulmonary arterial hypertension in the contemporary treatment era: a single centre retrospective study of 451 patients.
Effects on Right Ventricular size and function by Riociguat in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (The RIVER Study)
Relative bioavailability and pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet oral formulation and the effect of food and gender in healthy human subjects